Show simple item record

dc.creatorIaconis, Daniela
dc.creatorTalarico, Carmine
dc.creatorManelfi, Candida
dc.creatorCandida Cesta, Maria
dc.creatorZippoli, Mara
dc.creatorCaccuri, Francesca
dc.creatorMatusali, Giulia
dc.creatorBordi, Licia
dc.creatorScorzolini, Laura
dc.creatorBucci, Enrico
dc.creatorCaruso, Arnaldo
dc.creatorNicastri, Emanuele
dc.creatorAllegretti, Marcello
dc.creatorRosario Beccari, Andrea
dc.date.accessioned2022-04-22T20:27:58Z
dc.date.available2022-04-22T20:27:58Z
dc.date.issued2021-10-24
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/7571
dc.identifier.urihttp://hdl.handle.net/20.500.12613/7593
dc.description.abstractThe new coronavirus that emerged, called SARS-CoV-2, is the causative agent of the COVID-19 pandemic. The identification of potential drug candidates that can rapidly enter clinical trials for the prevention and treatment of COVID-19 is an urgent need, despite the recent introduction of several new vaccines for the prevention and protection of this infectious disease, which in many cases becomes severe. Drug repurposing (DR), a process for studying existing pharmaceutical products for new therapeutic indications, represents one of the most effective potential strategies employed to increase the success rate in the development of new drug therapies. We identified raloxifene, a known Selective Estrogen Receptor Modulator (SERM), as a potential pharmacological agent for the treatment of COVID-19 patients. Following a virtual screening campaign on the most relevant viral protein targets, in this work we report the results of the first pharmacological characterization of raloxifene in relevant cellular models of COVID-19 infection. The results obtained on all the most common viral variants originating in Europe, United Kingdom, Brazil, South Africa and India, currently in circulation, are also reported, confirming the efficacy of raloxifene and, consequently, the relevance of the proposed approach. Taken together, all the information gathered supports the clinical development of raloxifene and confirms that the drug can be proposed as a viable new option to fight the pandemic in at least some patient populations. The results obtained so far have paved the way for a first clinical study to test the safety and efficacy of raloxifene, just concluded in patients with mild to moderate COVID-19.
dc.format.extent19 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofCOVID-19 Research
dc.relation.isreferencedbybioRxiv
dc.rightsAttribution-NonCommercial-NoDerivs CC BY-NC-ND
dc.rights.urihttps://creativecommons.org/licenses/
dc.subjectCOVID-19
dc.subjectDrug repurposing
dc.subjectRaloxifene
dc.subjectEstrogen receptors
dc.subjectAntiviral activity
dc.subjectVero E6
dc.subject43 cells
dc.subjectCalu-3 cells
dc.subjectSARS-CoV-2 viral variants
dc.titleCharacterization of raloxifene as potential pharmacological agent against SARS-CoV-2 and its variants
dc.typeText
dc.type.genrePre-print
dc.contributor.groupSbarro Health Research Organization (Temple University)
dc.description.departmentBiology
dc.relation.doihttps://doi.org/10.1101/2021.10.22.465294
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.schoolcollegeTemple University. College of Science and Technology
dc.creator.orcidBucci|0000-0002-3317-8003
dc.temple.creatorBucci, Enrico
refterms.dateFOA2022-04-22T20:27:58Z


Files in this item

Thumbnail
Name:
Bucci-Preprint-2021.pdf
Size:
809.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs CC BY-NC-ND
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs CC BY-NC-ND